Kiadis Pharma to Receive GMP Manufacturing License and GMP Certificate
AMSTERDAM, July 23, 2013 /PRNewswire/ –
Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing treatments
for blood cancers, announced today that its Quality Control (QC) laboratory and the
associated Quality system has been inspected for good-manufacturing-practice (GMP) by the
Dutch Health Care Inspectorate (IGZ) and has fully met the EU GMP standards. As a result,
Kiadis Pharma will receive a GMP manufacturing license and GMP certificate for its QC
laboratory from the Dutch Ministry of Health, Welfare and Sport.
GMP licensing and certification enables Kiadis Pharma to perform QC release-assays for
the clinical trial manufacturing of the Company’s lead product ATIR(TM), a cellular
therapeutic that will enable partially mismatched donor stem cell transplants from family
members in blood cancer patients.
Manfred Ruediger, PhD, Chief Executive Officer of Kiadis Pharma, commented: “This is
an important milestone for Kiadis Pharma as we are committed to the highest standards of
manufacturing. We are delighted that our QC laboratory and the associated Quality system
will receive a GMP manufacturing license and GMP certificate. This not only attests to the
quality that we have established at Kiadis Pharma, but secures the pathway to take
ATIR(TM) to the next stage of development. ATIR(TM) is currently in an ongoing Phase II
study to confirm and extend some exciting data. We expect the Phase II results in H1
ATIR(TM) is a cell based medicinal product enabling stem cell transplantations using
partially mismatched (haploidentical) family members as donors for patients suffering from
blood cancer who lack a suitable standard of care matched donor. Stem cell transplantation
is the only potentially curative treatment for many patients but a matching donor is
available for only half of the patients in need. ATIR(TM) thus has the potential to
address this unmet need and to make stem cell transplantations available for all patients
Those T-cells in a haploidentical graft which would cause Graft-versus-Host-Disease
(GvHD) are selectively eliminated using proprietary technology to produce ATIR(TM).
ATIR(TM) is administered as an adjunctive treatment after a haploidentical stem cell
transplantation facilitating early immune reconstitution without causing life-threatening
In a Phase I/II study with ATIR(TM), safety and proof of concept were confirmed in
terms of absence of grade III/IV GvHD, reduced rates of infection, reduced Transplant
Related Mortality and high Overall Survival.
ATIR(TM) is currently in Phase II clinical development and has been granted Orphan
Drug Designation both in the EU and the USA. In these regions, 20,000 to 25,000 patients a
year are unable to find a suitable standard of care matched donor. Together, both regions
represent a combined primary market potential of more than EUR 1 billion per year.
About Kiadis Pharma
Kiadis Pharma B.V. is a private, clinical stage biopharmaceutical company developing
innovative and potentially life-saving therapies for patients with late stage blood
cancers and related disorders who are in need of a transplant, an area of significant
unmet medical need.
Kiadis Pharma’s lead product is ATIR(TM), a cell based product currently in Phase II
development, which is designed to enable stem cell transplantations from partially
mismatched (haploidentical) family donors. Kiadis Pharma is collaborating with
internationally renowned centers in Europe and North America for the successful
development and manufacturing of ATIR(TM).
Kiadis Pharma is supported by a strong group of leading international investors
including LSP, Alta Partners, DFJ Esprit, Quest for Growth, MedSciences Capital and NOM.
Kiadis Pharma is based in Amsterdam, The Netherlands. Further information can be found at:
Company Contact: Manfred Ruediger, CEO Kiadis Pharma Entrada 231-234 1096 EG AMSTERDAM The Netherlands Tel. +31-20-314-02-50 email@example.com Media and Investor Contact: Mary-Jane Elliott, Amber Bielecka, Lindsey Neville M:Communications Tel: +44-(0)207-920-2333 firstname.lastname@example.org
SOURCE Kiadis Pharma